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Abstract: Campylobacter species are a leading cause of bacterial-derived foodborne 
illnesses worldwide. The emergence of this bacterial group as a significant causative agent 
of human disease and their propensity to carry antibiotic resistance elements that allows 
them to resist antibacterial therapy make them a serious public health threat. 
Campylobacter jejuni and Campylobacter coli are considered to be the most important 
enteropathogens of this genus and their ability to colonize and survive in a wide variety of 
animal species and habitats make them extremely difficult to control. This article reviews 
the historical and emerging importance of this bacterial group and addresses aspects of the 
human infections they cause, their metabolism and pathogenesis, and their natural reservoirs 
in order to address the need for appropriate food safety regulations and interventions. 
Keywords: Campylobacter coli; Campylobacter jejuni; diarrhea; foodborne pathogen; 
Guillain Barré syndrome  
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1. The Genus Campylobacter  
Bacteria belonging to the genus Campylobacter are Gram-negative, spiral, non-spore forming rods 
that form spherical or coccoid bodies in older cultures [1]. They are between 0.2 to 0.9 microns wide 
and 0.5 to 5 microns long, are motile and usually move with a polar unsheathed flagellum at one or 
both ends, and are microaerobic with a respiratory-type metabolism, although there are some that grow 
aerobically or anaerobically [2]. The sequence of the genome of Campylobacter jejuni NCTC11168 
was originally published in 2000 [3]. There is considerable variation between strains and re-annotation 
of the C. jejuni genome published in 2006 revealed that the complete sequence is 1,641,481 bp in 
length with 25 polymorphic regions [4]. Moreover, new information for 1,450 of the original 1,654 
coding sequences revealed changes corresponding to over 300 product functions [4]. The infectious 
diseases caused by members of the bacterial genus Campylobacter are called campylobacteriosis [5]. 
Currently Campylobacter jejuni and Campylobacter coli are considered to be the most important 
enteropathogens among Campylobacter spp. [6]. The rate of Campylobacter infections are increasing 
worldwide, exceeding shigellosis [5,7]. 
2. Campylobacter Historical Perspective 
From a historical standpoint, the first report of Campylobacter is believed to have been made in 
1886 by Theodore Escherich, who observed and described a non-culturable spiral shaped bacteria, 
which he found in the colon of children with an enteric disease called “cholera infantum” [8–11]. 
Campylobacter was identified February 2, 1906 by two British veterinarians, John McFadyean and 
Stewart Stockman who reported the presence of “large numbers of a peculiar organisms” in Loeffler’s 
blue-stained smears of uterine mucus from a pregnant ewe [12]. In 1927, a group of vibrio-like 
bacteria was found in the feces of cattle with diarrhea. They were described by Theobold Smith and 
Marion Orcutt [6,13]. In 1931, Jones and coworkers showed a relationship between the 
microaerophillic vibrios and bovine dysentery, and the organism was eventually called Vibrio jejuni. 
The first well documented incident of Campylobacter infection took place in Illinois in 1938.  
The case involved a milk-borne outbreak of diarrhea that affected 355 inmates in two adjacent state 
institutions [14,15]. In 1944, Doyle isolated another vibrio from the feces of pigs with diarrhea and 
classified it as Vibrio coli [16,17]. Because of their low DNA base (low guanine and cytosine) 
composition, non-fermentative metabolism and their microaerophillic growth requirements the genus 
Campylobacter was proposed by Seabald and Vernon in 1963, distinguishing them from the  
Vibrio spp. [9,18]. There are two subspecies recognized within C. jejuni, C. jejuni subspecies jejuni and 
C. jejuni subspecies doylei. Strains of C. doylei differ from C. jejuni biochemically in its inability to reduce 
nitrate and variable growth at 42 °C [19]. Campylobacter coli and C. jejuni differ biochemically in their 
ability to hydrolyze hippurate. Campylobacter coli cannot hydrolyze hippurate and there are some  
C. jejuni subspecies that are hippurate negative [6]. 
3. Human Infections 
Campylobacter are a leading bacterial cause of zoonotic disease worldwide, affecting approximately 
1% of the human population in Europe each year [20] and infecting 13 of every 100,000 persons in the 
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United States annually [21]. Clinical manifestations of campylobacteriosis are largely undistinguishable 
from other bacterial gut infections and include fever, abdominal cramping, and diarrhea, with or without 
blood in stools [6,22]. These symptoms can last from three days to one week [23]. In severe cases of C. 
jejuni infection, individuals may exhibit fever, abdominal cramps and diarrhea that contain blood and 
leukocytes, or they may develop post infection complications associated with Guillain Barré Syndrome 
or Miller Fischer Syndrome. Miller Fischer Syndrome is a subform of Guillain Barré Syndome 
characterized by areflexia, ataxia and opthalmoplegia [6,24]. Campylobacter can also cause post-
infection complications associated with acquired immune-mediated neuropathies such as Guillian Barré 
Syndrome or Miller Fischer Syndrome [25,26]. In the developed world, most human Campylobacter 
infections are caused by Campylobacter jejuni; however, 4% of clinically confirmed cases in one study 
were attributed to Campylobacter coli [27]. Campylobacteriosis can occur in all age groups and the 
cost of human illness in the United States is estimated at $1.3 to 6.8 billion dollars annually [27,28]. 
In March of 2013 the Centers for Disease Control and Prevention (CDC) reported that in 2012 there 
was a 14% increase in the incidence of food-borne illness caused by Campylobacter jejuni [29].  
In 2005, the CDC estimated that the number of campylobacteriosis cases in the United States was 
about 1 million per year making it the second leading cause of laboratory confirmed cases of foodborne 
illness in the United States thus resulting in an estimated 12.72 cases per 100,000 people [30]. In 2009, 
the Foodborne Disease Active Surveillance Network (FoodNet) of the CDC estimated that the number 
of infections by Campylobacter was a total of 6,033, or 13.02 per 100,000 people [9]. In the last five 
years the European Food Safety Authority (EFSA) and the European Centre for Disease Prevention 
and Control (ECDC) reported that campylobacteriosis has become the most often reported zoonosis in 
the European Union followed by salmonellosis and yersinosis [9,31,32]. More than 200,000 confirmed 
cases of campylobacteriosis were reported in 24 of the member states of the European Union at a rate 
of 45.2 cases per 100,000 people. In 2010 New Zealand reported the highest national campylobacteriosis 
rate, which peaked in May 2006 at 400 per 100,000 population [9]. In general, developing countries do 
not have national surveillance programs for campylobacteriosis; consequently, there are no case 
incidence values in terms of population density [7]. Most of the estimates of incidence are done by 
laboratories where the surveillance is based on pathogens responsible for diarrhea.  
Campylobacter isolation rates in developing countries range from 5 to 20% [7,33]. Most of the data 
was collected by the World Health Organization (WHO), which along with the Canadian Public Health 
Service have provided financial support to developing countries for epidemiologic studies [7,34]. 
There is a large disparity in the incidence of campylobacteriosis in developing countries versus that of 
developed countries. High numbers of children in developing countries are affected by Campylobacter 
infections. Community based studies in developing countries have estimated that 60,000 per 100,000 
children <5 years of age [7,34,35]. This data suggests that campylobacteriosis is a pediatric disease in 
developing countries. In developed countries, more than 90% of human campylobacteriosis cases occur 
during the summer because of undercooked meats from outdoor cooking facilities. People of all ages are 
affected, but particularly children less than 4 years of age and young adults 15–44 years of age [14,28].  
The infectious dose of Campylobacter jejuni for humans is estimated to be low; between 500–800 
organisms [6]. The dosage was estimated in 1981 as a result of a human experiment in which a British 
medical doctor, Robinson, swallowed 500 organisms of known serotype in 180 mL of pasteurized  
milk [6,36]. The findings from this self-inflicted experiment, which reportedly satisfied the criteria of 
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Koch’s Postulates and the findings of additional human experiments, verified a dosage and a 
mechanism of C. jejuni human infection [6]. 
Campylobacter are also recognized as reservoirs for antimicrobial resistance genes that potentially 
can be exchanged between other pathogenic and commensal bacteria [37–40]. A 2011 review article 
hypothesizes that decades of indiscriminant use of antibiotics in food animal production may have led 
to the emergence and spread of antibiotic resistance among Campylobacter spp. [41]. The evidence of 
this is strongly supported [9].  
Antibiotics have been used for decades in food production animals to control, prevent,  
and treat infections and to enhance growth [9,42,43]. This usage has caused an increased resistance to 
multiple antibiotics by members of Campylobacter spp. in food production animals and  
environments [9,44]. The development of antimicrobial resistance in Campylobacter spp. is a serious 
threat to human health [9]. Worldwide, there has been a rapid increase in the proportion of 
Campylobacter strains resistant to antimicrobial agents [37,45–47]. Campylobacter jejuni and C. coli 
are almost intrinsically resistant to penicillians, cephalosporins (with exception of a few 3rd generation 
cephalosporins), trimethoprim, sulfamethoxazole, rifampicin and vancomycin [6]. For patients infected 
with Campylobacter spp., the prognosis is that most will recover without specific treatments other than 
replacement of fluid and electrolytes, however, in severe cases antibiotics such as macrolides and 
fluroquinolones are generally administered [9]. It is believed that increasing resistance to 
fluroquinolones and erythromycin by C. jejuni and C. coli might compromise the effectiveness of these 
treatments [37,47–49]. 
4. Campylobacter Metabolism 
Although there has been a significant amount of knowledge elucidated about the Campylobacter 
genus, there is still more to learn about Campylobacter’s metabolic processes. For instance, the process 
of nutrient acquisition by Campylobacter has not been completely elucidated but it is apparent this 
process is flexible enough to allow survival in the environment (water, food or feces) before host 
ingestion [50]. Unlike many other gut bacteria, however, Campylobacter are limited in their ability to 
conserve energy for growth and maintenance via fermentation of carbohydrates. These bacteria lack  
6-phophofructokinase, which is a key enzyme in energy metabolism [51], although a novel L-fucose 
pathway has been elucidated by Muraoka and Zhang [52] and Stahl [53]. Moreover, Campylobacter 
are further limited in their ability to conserve energy for growth via fermentation of carbohydrates due 
to the absence an active phosphoenolpyruvate dependent phosphotransferase system, which would 
function to transport and phosphorylate sugars simultaneously [6,51]. Campylobacter can conserve 
energy via respiration, oxidizing hydrogen and formate for the reduction of the electron acceptors 
(fumarate, nitrate, sulfites) and, if at low concentrations, oxygen, to generate proton motive force for 
electron transport phosphorylation [51,54–57]. Campylobacter jejuni relies on the use of the amino acids 
and the citric acid cycle intermediates as carbon sources [58]. Campylobacter jejuni utilize available 
amino acids in a sequential order, with preference to, serine, aspartate, asparagine, and glutamate and 
other C. jejuni strains have been found to metabolize proline but only after all other amino acid sources 
have been completely utilized [50]. Campylobacter can conserve energy via respiration, oxidizing 
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hydrogen and formate for the reduction of electron acceptors such as fumarate, nitrate, sulfites and if at 
low concentrations, oxygen, to generate proton motive force transport. 
There are some C. jejuni subspecies doylei which contain some enzymes from the  
Entner-Doudoroff pathway which convert glucose-6-phosphate to glyceraldehyde-3-phosphate 
utilizing gluconate-6-phosphate instead of a fructose-6-phosphate intermediate. This pathway 
eliminates the need for phosphofructokinase [6]. It has generally been assumed that C. jejuni were 
found to contain genomic islands (cj0480c-cj0490) that are up regulated in the presence of L-fucose 
and mucin obtained from the host during colonization in the intestine [53]. The current knowledge of 
C. jejuni in vivo metabolism is based on amino acid utilization to support the growth and establishment 
of colonization in the host intestines. Campylobacter jejuni’s metabolic diversity is evidenced by its 
differential carbon utilization [52,59,60]. 
5. Campylobacter Pathogenesis and Disease 
The exact sequential steps of C. jejuni infection to C. jejuni mediated enteritis are unknown.  
What is known are the requirements for C. jejuni virulence: (1) motility, (2) drug resistance,  
(3) host cell adherence, (4) host cell invasion, (5) alteration of the host cell signaling pathways,  
(6) induction of host cell death, (7) evasion of the host (8) immune system defenses, and (9) acquisition 
of iron which serves as a micronutrient for growth and works as a catalyst for hydroxyl radical 
formation [61–66]. It is also known that C. jejuni secretes proteins that contribute to the ability of the 
bacterium to invade the host epithelial cells [61]. Survival in the host environment depends on several 
adaptive responses including adherence, protein secretion, invasion and replication.  
The biochemical effects on cellular events are as follows: (1) cytoskeletal rearrangement,  
(2) host cell death, (3) tight junction disruption and cytokine induction that leads to loss of epithelial 
cell function, (4) a compromised barrier and absorptive functions, and (5) tissue destruction and 
disease manifestation. Adherence can also lead to an early inflammatory response that causes 
stimulation of innate immune functions in the following sequence: (1) an influx of fluid,  
(2) complement cell activation, (3) recruitment of phagocytes that can lead to C. jejuni lysis or death, 
(4) clearing of the infection or the presentation of antigens, (5) a humoral response and, (6) a clearing 
of the infection. In the other direction, instead of C. jejuni lysis or death, the inflammatory response 
could lead to tissue destruction and disease manifestation [61]. 
There is evidence that C. jejuni infections commonly precede Guillain Barré Syndrome which 
results from a case of molecular mimicry whereby host produced anti-Campylobacter antibodies 
recognize and cross react with self gangliosides and damage peripheral nerve tissue [6]. Guillain Barré 
Syndrome is a rare autoimmune disease characterized by the demyelination of motor and sensory nerves or 
deterioration of axonal nerves of the peripheral nervous system. This nerve damage can lead to muscle 
weakness, paralysis, and death. It is reported that Guillain Barré Syndrome “has become the most frequent 
cause of acute flaccid paralysis since the near elimination of poliomyelitis in the world” [26,67–69].  
Studies have established Guillain Barré Syndrome as a mechanism of molecular mimicry based on 
Koch’s and Witebsky’s postulates. They are as follows: (1) the establishment of an epidemiological 
association between the infectious agent and the autoimmune disease, (2) the identification of T cells 
or antibodies directed against the patient’s target antigens, (3) the identification of microbial mimics of 
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the target antigen, and (4) reproduction of the disease in an animal model. Autoantibodies are the 
pathogenic component that triggers Guillain Barré Syndrome [68].  
There are two major sub-forms of Guillain Barré Syndrome that affect the peripheral nervous 
system. The major sub-forms of Guillain Barré Syndrome are: (1) acute inflammatory demyelinating 
polyneuropathy characterized by the demyelination of peripheral nerves, (2) acute motor axonal 
neuropathy characterized by degeneration of axonal components of peripheral nerves, and (3) Miller 
Fischer syndrome characterized by areflexia, ataxia, and ophthalmoplegia. Studies have indicated that 
C. jejuni infection precedes Guillain Barré Syndrome in 20 to 50% of cases in Europe, North and 
South America, Japan, and Austraila. The percentage is suspected to be higher in developing countries. 
Since Campylobacter infections occur far more frequently than Guillain Barré Syndrome, neither the 
characteristics of the host nor the strain of Campylobacter species are known determinants of which 
persons with Campylobacter infection contract Guillain Barré Syndrome. Guillain Barré Syndrome 
usually develops 1 to 3 weeks after a C. jejuni infection. Studies in Japan have indicated that the risk of 
developing Guillain Barré Syndrome may be higher after infection with C. jejuni type O:19 [6,26,67]. 
6. Reservoirs of Campylobacter 
In developing countries Campylobacter infection is said to be hyperendemic and major sources of 
infection are environmental and food contamination [7]. Conversely, food production animals are 
considered to be the primary source of Campylobacter infections in humans in developed countries 
such as the United States. From animal farms to the commercial production of food commodities there 
are numerous possibilities for transmission of Campylobacter infection through cross-contamination. 
Campylobacter infection from consumption of poultry, beef, and pork products is the leading cause of 
human foodborne illness. Poultry is estimated to account for 50%–70% of human Campylobacter 
infection. Poultry includes broilers, laying hens, turkeys, ducks, and ostriches [6]. Studies have indicated 
that the prevalence of Campylobacter colonization in cattle is 0%–80% and 20% in sheep.  
The same study reported that pigs were more contaminated than cattle or sheep [70]. Poultry and poultry 
products are considered to be the largest contributor of human Campylobacter infection. 
Campylobacter jejuni mainly colonizes poultry and is found predominantly in the cecum and colon, 
but it can also be found in the crops. Horrocks et al. speculated that due to the higher metabolic 
temperatures of the poultry species they are possibly predisposed to become prominent reservoirs for 
the thermotolerant C. jejuni [71]. 
Campylobacter transmission is prevalent during preharvest conditions. Colonization in broiler 
chicks has been demonstrated to be a risk factor in horizontal transmission of C. jejuni infection. 
Broiler chick colonization is estimated to take place no sooner than seven days of age [70,72].  
Other studies have found that broiler chick colonization takes from zero to three weeks. Colonization of 
free-ranging chickens is estimated to take place from 0–8 days [71,73–75]. Although young animals 
are very susceptible to colonization by C. jejuni, older broiler chicks closer to processing age have a 
higher percentage of Campylobacter colonization. Despite horizontal transmission of the flock taking 
place rapidly, colonization of the flock can take up to several weeks [71]. Studies have estimated that 
up to 98% in the United States and 60% to 80% in Europe of retail chicken meat is contaminated with 
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C. jejuni [73]. It was found that the skin and giblets have particularly high concentrations of 
Campylobacter contamination [73]. 
Despite the consistent implication that Campylobacter colonization of poultry and poultry products 
is the major contributor to human foodborne illness, cattle and other swine frequently carry C. jejuni 
and C. coli [76–81]. It is probable that cattle carcasses are contaminated during processing either 
directly or indirectly. None the less, the cases of human foodborne illness as a result of Campylobacter 
contamination in bovine products (unpasteurized milk and meat) is a legitimate concern [76,77]. 
Multiple studies with cattle have shown that Campylobacter preferentially colonize the lower 
gastrointestinal tract as opposed to the upper gastrointestinal tract (the 1st stomach) where there is a 
lower pH environment in the rumen [78]. Additionally the stratified epithelium of the rumen probably 
lacks the necessary receptors to sustain a persistent high level of Campylobacter colonization [78].  
The gallbladder, liver and bile have all been shown to harbor moderately high percentages of 
Campylobacter. In recent studies, 33% and 21.8% respectively of samples tested positive for 
Campylobacter in the gallbladder, its mucosal tissue and bile [71,79–81]. Unpasteurized bovine milk 
and milk products are common vehicles for Campylobacter foodborne disease transmission. In a study 
with cattle from a dairy farm 12% of raw milk samples were found to be contaminated with C. jejuni 
possibly as a result of contact with bovine feces, contaminated water or direct contamination as a result 
of mastitis [41]. 
The incidence of Campylobacter is reported to be lower for forage fed (primarily dairy cattle) than 
that of feedlot cattle. The possible contributors to the high incidence of Campylobacter in feedlot cattle 
are: (1) increased stocking densities, (2) constant contact with feces from other animals, and (3) the high 
frequency of shared access to community feeding and water troughs [71,82]. These studies found that 
there was a higher prevalence of Campylobacter in feedlot cattle (68%) compared to that of adult cattle 
from the pasture (7.3%) and others found that prevalence rates increased in fed cattle from 1.6% near 
or upon entry to the feedlot to 63% near the end of the finishing period [76]. Prevalence numbers 
remained relatively the same whether tests were conducted before or after transport to processing [82]. 
These results suggest that confinement may promote increased carriage and horizontal transmission of 
Campylobacter. Further swab tests on the hides of these cattle yielded the same results. The feedlot cattle 
had significantly more contaminated hides [82]. 
The numbers of swine that are colonized by Campylobacter are more comparable to cattle than to 
those of poultry. Campylobacter coli, which normally inhabit pig intestines, are also found on pork 
products. Swine are predominantly colonized with C. coli albeit less frequently they are colonized with 
C. jejuni [79]. Young et al. [80] demonstrates that despite the prevalence of C. coli in swine,  
a high prevalence of C. jejuni enteric colonization (cecal or rectal contents) has been observed in gilts, 
sows, and weaned piglets. Studies conducted by Jensen et al. [71,81] investigated C. jejuni versus C. coli 
colonization of outdoor organically-reared pigs to monitor possible shifts from C. coli to C. jejuni 
intestinal colonization. Their findings from three research trials indicated that there were excessive 
fluctuations (0%, 18.8% and 78.6%) of swine colonized by C. jejuni, and in each trial swine were still 
dominantly colonized by C. coli [81]. There have also been research studies that demonstrate the 
possible co-existence of C. coli and C. jejuni in pigs with C. jejuni being present in lower numbers [81,83]. 
In these studies; however, C. jejuni was never found to be more prevalent than C. coli. 
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The life of swine raised for food production starts at a farrowing barn where they are born.  
After three weeks they are moved to a nursery where they will stay until they reach 22.6 kg (6 weeks). 
Next they are moved to a finishing unit where they will stay until they reach market growth rate  
(99.8–113.4 kg). Environmental conditions naturally play an important role in Campylobacter transmission 
in swine the same as in cattle and poultry. There are increased possibilities for Campylobacter infection 
and disease transmission in finishing units and breeding farms [80]. There are distinct differences in the 
prevalence and occurrence of Campylobacter colonization and infection of pigs raised in organic outdoor 
production systems than those raised in conventional farm systems [84]. 
7. Conclusions 
Recent reported increases of Campylobacter infections attributed to foodborne illness in the  
United States and elsewhere indicate that Campylobacter continues to be an emerging pathogen 
worldwide. Therefore it is imperative that the food industries recognize the increased persistence of 
Campylobacter infections as a serious public health risk and take measures to improve food safety by 
making pre and post-harvest practices more stringent. Efforts to reduce or eliminate Campylobacter 
contamination in the food industry needs to become a more determined priority. Poultry and poultry 
products remain the number one cause of foodborne illness worldwide. Effective pre-harvest 
interventions that reduce the concentration and prevalence of Campylobacter in food producing 
animals are needed for all animal species. Current post harvest interventions are limited to non-specific 
hygienic controls and new and more specific interventions are needed to help reduce product 
contamination. The consumption of undercooked poultry products and the cross-contamination of 
carcasses and other food products continues to be a major public health concern. The continual 
emergence of antibiotic resistant Campylobacter infections poses a serious public health concern in 
addition to the fact that there are still many aspects about the Campylobacter species physiology that 
we have not elucidated. All of the factors stated above increase the need for more stringent food safety 
regulations, new research and application of new and improved pre-harvest and post-harvest strategies. 
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